Asia Pacific Vaccines Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 9,048.51 Million |
 Taille du marché (année de prévision) |
USD 18,031.69 Million |
 TCAC |
% |
| Principaux acteurs du marché |
Marché des vaccins en Asie-Pacifique, par composition (vaccins combinés et monovaccins), type (vaccins sous-unitaires, recombinants, polysaccharidiques et conjugués, vaccins vivants atténués, vaccins inactivés et vaccins toxoïdes), type (vaccin de routine, vaccin recommandé et vaccin requis), âge d'administration (vaccin pédiatrique et vaccin adulte), maladies (pneumococcie, rougeole, oreillons et varicelle, DTC, hépatite, grippe, typhoïde, méningocoque, rage, encéphalite japonaise, fièvre jaune et autres), voie d'administration (injectable, orale et nasale), utilisateur final (hôpitaux communautaires, hôpitaux, centres spécialisés, cliniques et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail et pharmacie en ligne) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché des vaccins en Asie-Pacifique
La prévalence croissante des maladies infectieuses, notamment bactériennes et virales, assure au marché une croissance lucrative. Parallèlement à cela, l'augmentation du soutien gouvernemental et le lancement de nouveaux vaccins stimulent également le marché des vaccins. Un autre facteur qui stimule la croissance du marché des vaccins est la sensibilisation accrue à la vaccination et la demande de vaccins efficaces contre la COVID-19.
Le marché des vaccins en Asie-Pacifique devrait croître au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 9,4 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 18 031,69 millions USD d'ici 2030 contre 9 048,51 millions USD en 2022.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par composition (vaccins combinés et monovaccins), type (vaccins sous-unitaires, recombinants, polysaccharidiques et conjugués, vaccins vivants atténués, vaccins inactivés et vaccins toxoïdes), type (vaccin de routine, vaccin recommandé et vaccin requis), âge d'administration (vaccin pédiatrique et vaccin adulte), maladies (pneumococcie, rougeole, oreillons et varicelle, DTC, hépatite, grippe, typhoïde, méningocoque, rage, encéphalite japonaise, fièvre jaune et autres), voie d'administration (injectable, orale et nasale), utilisateur final (hôpitaux communautaires, hôpitaux, centres spécialisés, cliniques et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail et pharmacie en ligne) |
|
Pays couverts |
Japon, Chine, Australie, Inde, Corée du Sud, Singapour, Indonésie, Thaïlande, Malaisie, Philippines, Vietnam et reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
Bharat Biotech, Biological E Limited, Bio Farma, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd, and BAXTER VACCINES (a subsidiary of Baxter), among others |
Market Definition of Asia-Pacific Vaccines Market
Vaccines are product that stimulates the individual immune system to induce immunity against a particular disease. Vaccines work on the principle of memory and recognition. When weakened or killed microbes are injected into a body, these microbes cause B cells, memory cells of the immune system, to recognize the pathogen. In the future, if the same pathogen attacks the body, it works against those. Vaccines have been discovered for infectious diseases, including pneumococcal disease, measles, mumps, rubella, hepatitis, influenza, typhoid, varicella, and rabies.
Vaccines are of two types: combination vaccines (containing different strains of the pathogen) and monovaccines (containing a single strain of the pathogen). Different kinds of vaccines have been developed based on the material extracted from the pathogen, which can be polysaccharide coat, DNA, RNA, and the whole organism, either inactivated or live.
These are the vaccines that resulted in the eradication of diseases such as polio. As per the preference and efficiency of vaccines, these can be injected via several routes of administration that can be injectable, oral, or nasal. However, the injectable route of vaccine administration is highly preferred as it induces a systemic response. Vaccination can be achieved at hospitals, community clinics, and specialty clinics, among others, by trained personnel having appropriate knowledge about vaccine administration devices.
The increasing prevalence of infectious diseases, including bacterial and viral diseases, provides the market with lucrative growth. Along with this, increasing government support and the launch of newer vaccines also boost the vaccine market. Another factor boosting the vaccine market growth is increasing vaccination awareness and demand for effective COVID-19 vaccines.
Asia-Pacific Vaccines Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
GROWTH IN THE IMMUNIZATION PROGRAMS AND CAMPAIGNS
Immunization programs and campaigns are increasing worldwide because of an increasing number of chronic diseases. As hepatitis, diphtheria, pertussis, and polio, among other infectious diseases, are prevailing in the environment, there is an urgent need to increase awareness regarding vaccination which can be achieved by launching several campaigns and programs. This has been reported that the number of immunization programs is increasing with an increase in infectious diseases. Immunization coverage is also increasing worldwide, intending to fight against debilitating diseases.
Still, around 20 million people remain unvaccinated and under-vaccinated, raising a great demand for vaccination. The prevalence of chronic diseases is increasing worldwide. Hence the need to get vaccinated is great. This signifies that a growing immunization program and the campaign are expected to grow the vaccine market.
HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU, INFECTIOUS AND VIRAL DISEASES
The prevalence of infectious diseases is increasing worldwide, and this has been seen that flu and bacterial infectious disease are surging rapidly. This increasing rate of infectious diseases has created the need for disease prevention which can be prevented by vaccination or immunization. As diseases are increasing significantly, there is an urgent need for mass vaccination. Mass vaccinations require many diseases, hence expected to provide the vaccine market with lucrative growth.
As the disease cases are increasing, the focus on mass vaccination is also increasing to prevent large population size. Many people who have not received vaccination at a younger age are immunized worldwide. So, to cater such needs, the demand for novel vaccines is increasing and hence expected to act as a driver in the Asia-Pacific vaccines market.
RESTRAINT
UNAVAILABILITY OF REGISTERED VACCINES
The strict regulatory approvals and time taking development procedures for the vaccines are some of the factors that are responsible for the unavailability of registered vaccines. The regulatory authorities find difficulties in the vaccines' assessment, licensure, control, and surveillance. The world supply of vaccines is delayed due to these regulations.
Therefore, the regulation processes and document formation of the manufacturing companies in different countries can act as a restrain and hamper the growth of the vaccines market.
OPPORTUNITY
STRATEGIC INITIATIVES BY THE MARKET PLAYERS
Market players adopt various strategic initiatives in the vaccines market that involve expansion, collaboration, and acquisition. These initiatives allow them to increase the company's product portfolio, leading to market expansion and enhancing the product demand among customers, which ultimately allows the market players to earn maximum revenue.
As the demand for effective and novel vaccines is increasing worldwide, these strategic initiatives taken by top market players aim at enhancing business operations and earning more profitability in the market.
Various strategic initiatives adopted by the market players allowed them to expand its root in vaccines and earn more market growth. Thus, the market players operating in vaccines are adopting several strategic initiatives expected to act as an opportunity for the vaccine market growth.
CHALLENGE
SIDE EFFECTS CAUSED BY VACCINES
The vaccine is a medical product that helps in preventing different diseases. But sometimes, side effects arise due to the use of the vaccines. Some of them are mild side effects which are redness, soreness, or swelling at the injection site. But the adverse side effects of the vaccines are rare but are life-threatening.
The life-threatening side effects can give rise to fear in the population's mind. Moreover, it impacts the credibility of vaccine manufacturers, affecting product sales. This thus suggests that side effects caused by vaccines may hamper the growth of the vaccines market.
Recent Developments
- In October 2022, Indonesia Launched its First Home-Grown COVID-19 Vaccine. IndoVac vaccine has been developed jointly by Indonesia's state-owned pharmaceutical company Bio Farma and the Baylor College of Medicine, an independent health sciences center in Houston, Texas
- In November 2020, Merck Sharp & Dohme Corp., a Merck & Co., Inc. subsidiary, signed an agreement to acquire OncoImmune, a clinical-stage biopharmaceutical company. The OncoImmune Company is highly focused on the development of COVID-19 treatment options. Through this agreement, the company is expecting to develop new vaccine candidates
- In September 2020, Sanofi and GSK signed an agreement with the government of Canada to supply 72 million doses of COVID-19 vaccines. There is a high demand for COVID-19 vaccines, and the demand is increasing with the increasing pandemic. This agreement allowed the company to ensure future potential
Asia-Pacific Vaccines Market Scope
Asia-Pacific vaccines market is segmented into composition, type, kind, age of administration, diseases, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
COMPOSITION
- Combination vaccines
- Mono vaccines
On the basis of composition, the Asia-Pacific vaccines market is segmented into combination vaccines and monovaccines.
TYPE
- Subunit, recombinant, polysaccharide and conjugate vaccines
- Live-attenuated vaccines
- Inactivated vaccines
- Toxoid vaccines
Sur la base du type, le marché des vaccins de l'Asie-Pacifique est segmenté en vaccins sous-unitaires, recombinants, polysaccharidiques et conjugués, vaccins vivants atténués, vaccins inactivés et vaccins toxoïdes.
GENTIL
- Vaccin de routine
- Vaccin recommandé
- Vaccin obligatoire
Sur la base du type, le marché des vaccins de la région Asie-Pacifique est segmenté en vaccin de routine, vaccin recommandé et vaccin obligatoire.
ÂGE D'ADMINISTRATION
- Vaccin pédiatrique
- Vaccin pour adultes
Sur la base de l'âge d'administration, le marché des vaccins de la région Asie-Pacifique est segmenté en vaccins pédiatriques et vaccins pour adultes.
MALADIES
- Maladie pneumococcique
- Rougeole, oreillons et varicelle
- DPT
- Hépatite
- Grippe
- Typhoïde
- Méningocoque
- Varicelle
- Rage
- Encéphalite japonaise
- Fièvre jaune
- Autres
Sur la base des maladies, le marché des vaccins de l'Asie-Pacifique est segmenté en maladies pneumococciques, rougeole, oreillons et varicelle, DTP, hépatite, grippe, typhoïde, méningocoque, rage, encéphalite japonaise, fièvre jaune et autres.
VOIE D'ADMINISTRATION
- Injectable
- Nasale
- Oral
Sur la base de la voie d’administration, le marché des vaccins Asie-Pacifique est segmenté en vaccins injectables, oraux et nasaux.
UTILISATEUR FINAL
- Hôpitaux communautaires
- Hôpitaux
- Centres spécialisés
- Cliniques
- Autres
Sur la base de l’utilisateur final, le marché des vaccins de l’Asie-Pacifique est segmenté en hôpitaux communautaires, hôpitaux, centres spécialisés, cliniques et autres.
CANAL DE DISTRIBUTION
- Pharmacie hospitalière
- Pharmacie de détail
- Pharmacie en ligne
Sur la base du canal de distribution, le marché des vaccins en Asie-Pacifique est segmenté en pharmacie hospitalière, pharmacie de détail et pharmacie en ligne.
Analyse/perspectives régionales du marché des vaccins en Asie-Pacifique
Le marché des vaccins en Asie-Pacifique est analysé et des informations sur la taille et les tendances du marché sont fournies par pays, composition, type, nature, âge d'administration, maladies, voie d'administration, utilisateur final et canal de distribution, comme référencé ci-dessus.
Les pays couverts dans ce rapport de marché sont le Japon, la Chine, la Corée du Sud, l’Inde, l’Australie, Singapour, la Thaïlande, la Malaisie, l’Indonésie, les Philippines, le Vietnam et le reste de l’Asie-Pacifique.
Le Japon devrait dominer le marché des vaccins en Asie-Pacifique en termes de parts de marché et de revenus et devrait continuer à accroître sa domination au cours de la période de prévision. Cela est dû à une préférence croissante pour les examens de santé préventifs.
La section pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Les points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence des marques locales et nationales et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des vaccins en Asie-Pacifique
Le paysage concurrentiel du marché des vaccins fournit des détails sur un concurrent. Les détails comprennent la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus ne concernent que l'orientation des entreprises vers le marché des vaccins.
Français Certains des principaux acteurs opérant sur le marché des vaccins en Asie-Pacifique sont Bharat Biotech, Biological E Limited, Bio Farma, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corp. (une filiale de Merck & Co., Inc.), Abbott, AstraZeneca, Sanofi, Pfizer Inc., Janssen Global Services, LLC (une filiale de Johnson & Johnson Services, Inc.), F. Hoffmann-La Roche Ltd, Panacea Biotec Ltd et BAXTER VACCINES (une filiale de Baxter), entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC VACCINES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPOSITION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL MODEL
4.2 PORTER'S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 INDUSTRIAL INSIGHTS:
4.5 PIPELINE ANALYSIS
4.6 ASIA-PACIFIC VACCINES MARKET: SUPPLY CHAIN MANAGEMENT OF VACCINES
4.6.1 COLD CHAIN STORAGE:
4.6.2 PROCESS OF LOGISTICS
5 REGULATORY FRAMEWORK
5.1 JAPAN
5.2 CHINA
5.3 SOUTH KOREA
5.4 INDIA
5.5 AUSTRALIA
5.6 SINGAPORE
5.7 THAILAND
5.8 MALAYSIA
5.9 INDONESIA
5.1 VIETNAM
5.11 PHILIPPINES
5.12 REST OF ASIA-PACIFIC
5.12.1 TAIWAN
5.12.2 CAMBODIA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
6.1.2 HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU, INFECTIOUS AND VIRAL DISEASES
6.1.3 IMPROVEMENT IN TREATMENT
6.1.4 LAUNCH OF NEWER VACCINES
6.1.5 INCREASING GOVERNMENT SUPPORT
6.2 RESTRAINTS
6.2.1 UNAVAILABILITY OF REGISTERED VACCINES
6.2.2 DIFFICULTIES ASSOCIATED WITH THE TRANSPORT AND PRODUCTION OF VACCINES
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 PRESENCE OF PIPELINE PRODUCTS
6.3.3 RISE IN EXPENDITURE IN THE HEALTHCARE SECTOR
6.3.4 INCREASING AWARENESS FOR VACCINATION
6.4 CHALLENGES
6.4.1 SIDE EFFECTS CAUSED BY VACCINES
6.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
6.4.3 PRODUCT RECALL
7 ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION
7.1 OVERVIEW
7.2 COMBINATION VACCINES
7.3 MONO VACCINES
8 ASIA-PACIFIC VACCINES MARKET, BY TYPE
8.1 OVERVIEW
8.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES
8.2.1 PNEUMOCOCCAL DISEASE
8.2.2 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE
8.2.3 HPV (HUMAN PAPILLOMA VIRUS)
8.2.4 HEPATITIS B
8.2.5 MENINGOCOCCAL
8.2.6 SHINGLES
8.2.7 WHOOPING COUGH
8.2.8 OTHERS
8.3 LIVE-ATTENUTAED VACCINES
8.3.1 ROTAVIRUS
8.3.2 MEASLES
8.3.3 MUMPS
8.3.4 RUBELLA
8.3.5 SMALLPOX
8.3.6 YELLOW FEVER
8.3.7 OTHERS
8.4 INACTIVATED VACCINES
8.4.1 FLU (SHOT ONLY)
8.4.2 POLIO (SHOT ONLY)
8.4.3 HEPATITIS A
8.4.4 RABIES
8.4.5 OTHERS
8.5 TOXOID VACCINES
8.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP)
8.5.2 OTHERS
9 ASIA-PACIFIC VACCINES MARKET, BY KIND
9.1 OVERVIEW
9.2 ROUTINE VACCINES
9.2.1 PNEUMOCOCCAL DISEASES
9.3 DIPTHERIA, TETANUS & PERTUSIS(DPT)
9.3.1 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE
9.3.2 MEASLES
9.3.3 MUMPS
9.3.4 HEPATITIS B
9.3.5 RUBELLA
9.3.6 POLIO
9.3.7 OTHERS
9.4 RECOMMENDED VACCINE
9.4.1 TYPHOID FEVER VACCINE
9.5 HEPATITIS A
9.5.1 RABIES
9.5.2 JAPANESE ENCEPHALITIS
9.5.3 TICK-BORNE ENCEPHALITIS
9.5.4 CHOLERA
9.5.5 OTHERS
9.6 REQUIRED VACCINE
9.6.1 MENINGOCOCCAL
9.7 YELLOW FEVER
9.7.1 OTHERS
10 ASIA-PACIFIC VACCINES MARKET, BY AGE OF ADMINISTRATION
10.1 OVERVIEW
10.2 PEDIATRIC VACCINE
10.2.1 PNEUMOCOCCAL DISEASES
10.3 MEASLES, MUMPS & RUBELLA
10.3.1 DIPTHERIA, TETANUS & PERTUSIS (DPT)
10.3.2 ROTAVIRUS
10.3.3 MENINGOCOCCAL
10.3.4 VARICELLA
10.3.5 POLIO
10.3.6 TUBERCULOSIS
10.3.7 MALARIA
10.3.8 OTHERS
10.4 ADULT VACCINE
10.4.1 INFLUENZA
10.5 HPV (HUMAN PAPILLOMA VIRUS)
10.5.1 TYPHOID
10.5.2 HEPATITIS B
10.5.3 JAPANESE ENCEPHALITIS
10.5.4 YELLOW FEVER
10.5.5 CANCER
10.5.6 OTHERS
11 ASIA-PACIFIC VACCINES MARKET, BY DISEASES
11.1 OVERVIEW
11.2 PNEUMOCCOCAL DISEASE
11.3 MEASLES, MUMPS & RUBELLA
11.4 DPT
11.5 HEPATITIS
11.6 INFLUENZA
11.7 TYPHOID
11.8 MENINGOCOCCAL
11.9 VARICELLA
11.1 RABIES
11.11 JAPANESE ENCEPHALITIS
11.12 YELLOW FEVER
11.13 OTHERS
12 ASIA-PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INJECTABLE
12.2.1 INTRAMUSCULAR
12.2.2 SUBCUTANEOUS
12.2.3 INTRADERMAL
12.3 ORAL
12.4 NASAL
13 ASIA-PACIFIC VACCINES MARKET, BY END USER
13.1 OVERVIEW
13.2 COMMUNITY HOSPITALS
13.3 HOSPITALS
13.4 SPECIALTY CENTERS
13.5 CLINICS
13.6 OTHERS
14 ASIA-PACIFIC VACCINES MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 ASIA-PACIFIC VACCINE MARKET
15.1 ASIA-PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 AUSTRALIA
15.1.4 INDIA
15.1.5 SOUTH KOREA
15.1.6 SINGAPORE
15.1.7 MALAYSIA
15.1.8 THAILAND
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 REST OF ASIA PACIFIC
16 ASIA-PACIFIC VACCINES MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16.2 DISEASE SHARE ANALYSIS: PFIZER, INC.
16.3 COUNTRY SHARE ANALYSIS: PFIZER, INC.
16.4 DISEASE SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
16.5 COUNTRY SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
16.6 DISEASE SHARE ANALYSIS: GLAXOSMITHKLINE PLC
16.7 COUNTRY SHARE ANALYSIS: GLAXOSMITHKLINE PLC.
16.8 DISEASE SHARE ANALYSIS: SANOFI
16.9 COUNTRY SHARE ANALYSIS: SANOFI
16.1 DISEASE SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD.
16.11 COUNTRY SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD.
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY WEBSITE AND PRESS RELEASES
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 GLAXOSMITHKLINE PLC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENTS
18.4 SANOFI
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 SERUM INSTITUTE OF INDIA PVT. LTD.
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENTS
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ASTRAZENECA (2022)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ALK
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 BAXTER VACCINES (A SUBSIDIARY OF BAXTER)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BHARAT BIOTECH
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 BIO FARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENTS
18.12 BIOLOGICAL E LIMITED
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 DAIICHI SANKYO COMPANY, LIMITED
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 F. HOFFMANN-LA ROCHE LTD
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD.,
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 PANACEA BIOTEC LTD
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 SEQIRUS (A SUBSIDIARY OF CSL LIMITED)
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 COMPANY WEBSITE AND PRESS RELEASES
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Liste des tableaux
TABLE 1 ASIA-PACIFIC VACCINES MARKET, PIPELINE ANALYSIS
TABLE 2 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVELS OF THE COLD CHAIN.
TABLE 3 LOGISTICS PROCESS ACROSS DIFFERENT REGIONS.
TABLE 4 LAWS AND REGULATIONS IN TAIWAN
TABLE 5 VACCINES UNDER CLINICAL TRIAL
TABLE 6 THE SIDE EFFECTS RELATED TO THE VACCINES
TABLE 7 ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 8 ASIA-PACIFIC VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA-PACIFIC SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 10 ASIA-PACIFIC LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA-PACIFIC INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 12 ASIA-PACIFIC TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA-PACIFIC VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 14 ASIA-PACIFIC ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 15 ASIA-PACIFIC RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 16 ASIA-PACIFIC REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 17 ASIA-PACIFIC VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 18 ASIA-PACIFIC PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 19 ASIA-PACIFIC ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 20 ASIA-PACIFIC VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 22 ASIA-PACIFIC INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC VACCINES MARKET, BY END USER, 2022-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 25 ASIA-PACIFIC KNEE CARTILAGE REPAIR MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 26 JAPAN VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 27 JAPAN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 28 JAPAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 29 JAPAN LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 JAPAN INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 31 JAPAN TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 32 JAPAN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 33 JAPAN ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 34 JAPAN RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 35 JAPAN REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 36 JAPAN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 37 JAPAN PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 38 JAPAN ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 39 JAPAN VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 40 JAPAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 41 JAPAN INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 42 JAPAN VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 JAPAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 CHINA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 45 CHINA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 46 CHINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 47 CHINA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 CHINA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 49 CHINA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 50 CHINA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 51 CHINA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 52 CHINA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 53 CHINA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 54 CHINA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 55 CHINA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 56 CHINA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 57 CHINA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 58 CHINA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 59 CHINA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 60 CHINA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 61 CHINA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 AUSTRALIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 63 AUSTRALIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 AUSTRALIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 AUSTRALIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 66 AUSTRALIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 67 AUSTRALIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 AUSTRALIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 69 AUSTRALIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 70 AUSTRALIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 71 AUSTRALIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 72 AUSTRALIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 73 AUSTRALIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 74 AUSTRALIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 75 AUSTRALIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 76 AUSTRALIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 77 AUSTRALIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 78 AUSTRALIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 79 INDIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 80 INDIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 INDIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 82 INDIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 INDIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 84 INDIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 85 INDIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 86 INDIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 87 INDIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 88 INDIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 89 INDIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 90 INDIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 91 INDIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 92 INDIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 93 INDIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 94 INDIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 95 INDIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 INDIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 SOUTH KOREA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 98 SOUTH KOREA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 SOUTH KOREA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 SOUTH KOREA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 SOUTH KOREA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 SOUTH KOREA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 103 SOUTH KOREA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 104 SOUTH KOREA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 105 SOUTH KOREA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 106 SOUTH KOREA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 107 SOUTH KOREA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 108 SOUTH KOREA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 109 SOUTH KOREA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 110 SOUTH KOREA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 111 SOUTH KOREA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 112 SOUTH KOREA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 113 SOUTH KOREA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 SINGAPORE VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 115 SINGAPORE SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 116 SINGAPORE LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 SINGAPORE INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 SINGAPORE TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 SINGAPORE VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 120 SINGAPORE ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 121 SINGAPORE RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 122 SINGAPORE REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 123 SINGAPORE VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 124 SINGAPORE PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 125 SINGAPORE ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 126 SINGAPORE VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 127 SINGAPORE VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 128 SINGAPORE INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 129 SINGAPORE VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 130 SINGAPORE VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 131 MALAYSIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 132 MALAYSIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 MALAYSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 134 MALAYSIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 135 MALAYSIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 136 MALAYSIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 137 MALAYSIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 138 MALAYSIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 139 MALAYSIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 140 MALAYSIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 141 MALAYSIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 142 MALAYSIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 143 MALAYSIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 144 MALAYSIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 145 MALAYSIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 146 MALAYSIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 MALAYSIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 MALAYSIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 THAILAND VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 150 THAILAND VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 THAILAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 152 THAILAND LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 153 THAILAND INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 154 THAILAND TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 THAILAND VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 156 THAILAND RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 157 THAILAND REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 158 THAILAND VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 159 THAILAND PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 160 THAILAND ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 161 THAILAND VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 162 THAILAND VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 163 THAILAND INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 164 THAILAND VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 165 THAILAND VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 166 INDONESIA VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 167 INDONESIA VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 168 INDONESIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 169 INDONESIA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 170 INDONESIA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 171 INDONESIA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 172 INDONESIA VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 173 INDONESIA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 174 INDONESIA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 175 INDONESIA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 176 INDONESIA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 177 INDONESIA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 178 INDONESIA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 179 INDONESIA VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 180 INDONESIA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 181 INDONESIA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 182 INDONESIA VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 INDONESIA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 184 PHILIPPINES VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 185 PHILIPPINES VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 PHILIPPINES SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 187 PHILIPPINES LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 188 PHILIPPINES INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 189 PHILIPPINES TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 190 PHILIPPINES VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 191 PHILIPPINES ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 192 PHILIPPINES RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 193 PHILIPPINES REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 194 PHILIPPINES VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 195 PHILIPPINES PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 196 PHILIPPINES ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 197 PHILIPPINES VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 198 PHILIPPINES VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 199 PHILIPPINES INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 200 PHILIPPINES VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 201 PHILIPPINES VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 202 VIETNAM VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
TABLE 203 VIETNAM VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 204 VIETNAM SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 VIETNAM LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 206 VIETNAM INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 VIETNAM TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 VIETNAM VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 209 VIETNAM ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 210 VIETNAM RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 211 VIETNAM REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2021-2030 (USD MILLION)
TABLE 212 VIETNAM VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 213 VIETNAM PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 214 VIETNAM ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 215 VIETNAM VACCINES MARKET, BY DISEASE, 2021-2030 (USD MILLION)
TABLE 216 VIETNAM VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 217 VIETNAM INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 218 VIETNAM VACCINES MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 219 VIETNAM VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 220 REST OF ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 ASIA-PACIFIC VACCINES MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC VACCINES MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC VACCINES MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC VACCINES MARKET: ASIA-PACIFIC VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC VACCINES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC VACCINES MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC VACCINES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC VACCINES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC VACCINES MARKET: SEGMENTATION
FIGURE 10 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND THE HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE ASIA-PACIFIC VACCINES MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 THE COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC VACCINES MARKET IN 2023 & 2030
FIGURE 12 FDA REGULATORY REVIEW PROCESS OF VACCINES
FIGURE 13 PROCESS OF SPECIAL APPROVAL ON VACCINES DURING THE 2019 H1N1PDM PANDEMIC
FIGURE 14 REGULATION OVERVIEW FOR THERAPEUTICS IN SINGAPORE
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA-PACIFIC VACCINES MARKET
FIGURE 16 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, 2022
FIGURE 17 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, 2023-2030 (USD MILLION)
FIGURE 18 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, CAGR (2023-2030)
FIGURE 19 ASIA-PACIFIC VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC VACCINES MARKET: BY TYPE, 2022
FIGURE 21 ASIA-PACIFIC VACCINES MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 22 ASIA-PACIFIC VACCINES MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 23 ASIA-PACIFIC VACCINES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC VACCINES MARKET: BY KIND, 2022
FIGURE 25 ASIA-PACIFIC VACCINES MARKET: BY KIND, 2023-2030 (USD MILLION)
FIGURE 26 ASIA-PACIFIC VACCINES MARKET: BY KIND, CAGR (2023-2030)
FIGURE 27 ASIA-PACIFIC VACCINES MARKET: BY KIND, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, 2022
FIGURE 29 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 30 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 31 ASIA-PACIFIC VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, 2022
FIGURE 33 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 34 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 35 ASIA-PACIFIC VACCINES MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 37 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 38 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 39 ASIA-PACIFIC VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC VACCINES MARKET: BY END USER, 2022
FIGURE 41 ASIA-PACIFIC VACCINES MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 42 ASIA-PACIFIC VACCINES MARKET: BY END USER, CAGR (2023-2030)
FIGURE 43 ASIA-PACIFIC VACCINES MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 45 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 46 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 47 ASIA-PACIFIC VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 ASIA-PACIFIC VACCINE MARKET: SNAPSHOT (2022)
FIGURE 49 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2022)
FIGURE 50 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2023 & 2030)
FIGURE 51 ASIA-PACIFIC VACCINE MARKET: BY COUNTRY (2022 & 2030)
FIGURE 52 ASIA-PACIFIC VACCINE MARKET: BY COMPOSITION (2023-2030)
FIGURE 53 ASIA-PACIFIC VACCINES MARKET: COMPANY SHARE 2022 (%)
FIGURE 54 PFIZER, INC., ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 55 PFIZER, INC., ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
FIGURE 56 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 57 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
FIGURE 58 GLAXOSMITHKLINE PLC, ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 59 GLAXOSMITHKLINE PLC, ASIA-PACIFIC VACCINES MARKET: COMPANY SHARE 2022 (%)
FIGURE 60 SANOFI, ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 61 SANOFI ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
FIGURE 62 SERUM INSTITUTE OF INDIA PVT. LTD., ASIA-PACIFIC VACCINES MARKET: DISEASE SHARE 2022 (%)
FIGURE 63 SERUM INSTITUTE OF INDIA PVT. LTD. ASIA-PACIFIC VACCINES MARKET: COUNTRY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
